Business
Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights
- RADR® artificial intelligence ("A.I.") platform surpassed 1.2 billion datapoints - Advanced opportunities for LP-184 in glioblastoma, prostate and
About this update from Lantern Pharma Inc.
[{"type":"text","content":"- RADR® artificial intelligence (\"A.I.\") platform surpassed 1.2 billion datapoints\n - Advanced opportunities for LP-184 in glioblastoma, prostate and pancreatic cancers in collaboration with leading cancer research centers\n - Identified and validated additional genomically-driven cancer indications for LP-184\n - Advanced the development of LP-300 with a Phase 2 trial launch in NSCLC planned for Q3 2021\n - Initiated Antibody Drug Conjugate (\"ADC\") program with novel linking and conjugation technology\n - Strengthened balance sheet following January 2021 public offering of $69.0 million\n - Conference call scheduled for 4:00 p.m. ET today\n\n\nDALLAS, March 10, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"A.I.\") platform to transform oncology drug discovery and development today announced financial results for the fourth quarter and fiscal year ended December 31, 2020.\n\n \n \n \n \n \n \n\n \n\"2020 was a pivotal year for Lantern Pharma, marked by a series of financial, operational and drug development achievements. We believe each of these achievements further validates our unique capital-efficient business model that leverages the power of our proprietary RADR® A.I. platform with the knowledge and experience of our scientific team aimed at developing precision oncology drugs,\" stated Panna Sharma, President and CEO of Lantern Pharma. \"We anticipate 2021 to be a transformational year for Lantern and our shareholders as each of our drug programs progresses towards key milestones, including the initiation of a Phase 2 trial of LP-300 in NSCLC among non-smokers, IND-enabling studies of LP-184 in multiple solid tumors, advancing our ADC program, and continued growth in the biologically-relevant and curated data that powers our RADR® A.I. platform.\"\n\"As a result of our rapid development and operational progress after our June IPO, we were able to significantly strengthen our balance sheet with the closing of a $69.0 million public offering in January 2021. Our solid financial position is expected to fuel continued growth and evolution of our RADR® A.I. platform, accelerate the development of our portfolio of targeted oncology drug candidates and allow us to introduce additional targeted opportunities in a capit...